MOLM-13 is a very aggressive AML cell line selected for rapid growth in mice where even a 12 day increase is significant. The downside is it is not such a good model of human AML. The reason it was used in this study is it is forms EMD AML tumours in mice so it is a good model for measuring how your drug works on the EMD form of AML - people will not be surprised to learn that bisantrene works well on the MOLM-13 EMD tumours.
The more important data is the PDX AML 16 results where the median survival improvement was huge (34 to 111 days). PDX stands for Patient Derived Xenografts - basically these are not cell lines, but primary cancers taken from patients and put into mice. PDXs behave much closer to the cancer in a patient and are a much better models of what to expect from a treatment when it is used in humans.
MOLM-13 is a very aggressive AML cell line selected for rapid...
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.045(3.14%) |
Mkt cap ! $248.8M | |||
| Open | High | Low | Value | Volume |
| $1.42 | $1.48 | $1.41 | $74.60K | 51.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6944 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 3096 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.47 |
Change
0.045 ( 1.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.41 | $1.48 | $1.41 | 21844 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| RAC (ASX) Chart |